Wordless Music and Sister Midnight, in collaboration with KCRW, announce a year-long series of screenings with live film ...
Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively1,318 patient start forms received in ...
Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. The stock rose 14%, to $17.99, in ...
Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...
Stocktwits on MSN
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart
KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...
DRIPA was introduced in 2019 to align B.C. law with a United Nations declaration affirming the worldwide right to ...
Is artistic talent hereditary or is it learned? In families with several great musicians, like the Bach or the Strauss ...
Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback